ADReCS

Pharmaceutical Information

Drug Name	Carboplatin
Drug ID	BADD_D00364
Description	Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage	Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status	approved
ATC Code	L01XA02
DrugBank ID	DB00958
KEGG ID	D01363
MeSH ID	D016190
PubChem ID	426756
TTD Drug ID	D0X7HM
NDC Product Code	0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII	BG3F62OND5
Synonyms	Carboplatin \| cis-Diammine(cyclobutanedicarboxylato)platinum II \| CBDCA \| Paraplatin \| Paraplatine \| Platinwas \| Ribocarbo \| Carboplat \| Neocarbo \| Carbosin \| Carbotec \| Ercar \| JM-8 \| JM 8 \| JM8 \| Nealorin \| NSC-241240 \| NSC 241240 \| NSC241240 \| Blastocarb

Chemical Information

Molecular Formula	C6H12N2O4Pt
CAS Registry Number	41575-94-4
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Abdominal discomfort	07.01.06.001	-	-	Not Available
Abdominal pain	07.01.05.002	0.010185%
Abdominal pain lower	07.01.05.010	-	-	Not Available
Abdominal pain upper	07.01.05.003	0.003794%
Actinic keratosis	23.01.06.001	0.000112%		Not Available
Acute hepatic failure	09.01.03.001	0.000280%		Not Available
Acute lymphocytic leukaemia	16.01.01.001; 01.10.01.001	0.000224%		Not Available
Acute myeloid leukaemia	16.01.05.001; 01.10.05.001	0.001119%		Not Available
Acute myocardial infarction	24.04.04.001; 02.02.02.001	0.000728%		Not Available
Acute promyelocytic leukaemia	01.10.05.003; 16.01.05.003	0.000168%		Not Available
Acute pulmonary oedema	22.01.03.005; 02.05.02.004	0.000168%		Not Available
Acute respiratory distress syndrome	24.03.02.034; 10.02.01.067; 22.01.03.001	0.000560%
Acute respiratory failure	22.02.06.001; 14.01.04.004	0.000728%		Not Available
Adenocarcinoma	16.16.01.004	0.000224%		Not Available
Agranulocytosis	01.02.03.001	0.000728%		Not Available
Alopecia	23.02.02.001	0.005675%
Altered state of consciousness	19.07.01.003; 17.02.04.001	0.000392%		Not Available
Anaemia	01.03.02.001	0.008831%
Anaphylactic reaction	10.01.07.001; 24.06.03.006	0.006111%
Anaphylactic shock	24.06.02.004; 10.01.07.002	0.005652%		Not Available
Anaphylactoid reaction	24.06.03.007; 10.01.07.003	0.000224%		Not Available
Angina pectoris	02.02.02.002; 24.04.04.002	0.000414%
Angioedema	22.04.02.008; 23.04.01.001; 10.01.05.009	0.001455%		Not Available
Anuria	20.01.03.002	0.000448%		Not Available
Apnoea	22.02.01.001	0.000112%
Arterial thrombosis	24.01.01.002	0.000280%		Not Available
Arteriospasm coronary	12.02.01.031; 24.04.04.005; 02.02.02.005	0.000112%		Not Available
Arthralgia	15.01.02.001	-	-
Ascites	09.01.05.003; 07.07.01.001; 02.05.04.002	0.001175%
Aspartate aminotransferase increased	13.03.04.011	-	-

The 1th Page 1 2 3 4 5 Next Last Total 21 Pages